FDA Extends Comment Period on ANDA Rule
FDA extends ANDA rule comment period to June 8, 2015 after requests for more time.
FDA announced on April 15, 2015 that it was extending the comment period for the agency’s proposed rule on abbreviated new drug applications (ANDAs) and 505(b)(2) applications to June 8, 2015, in response to requests for more comment time. The rule, published in the Federal Register on Feb. 6, 2015, was proposed “to implement portions of Title XI of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, which amended provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) that govern the approval of 505(b)(2) applications and ANDAs. FDA also requested comment on its proposal to amend certain regulations regarding 505(b)(2) applications and ANDAs to facilitate compliance with and efficient enforcement of the FD&C Act.”
Comments can be submitted online using docket number FDA-2011-N-0830.
Source: FDA.gov
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
